Cargando…
Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer
Pegylated liposomal doxorubicin (PLD) has become a major component in the routine management of epithelial ovarian cancer. The drug is frequently employed as a single agent in the platinum-resistant setting, and recently reported data reveal the superiority of the combination of PLD plus carboplatin...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139482/ https://www.ncbi.nlm.nih.gov/pubmed/21792330 http://dx.doi.org/10.2147/CMR.S15558 |